Absci Corporation announced a collaboration with Memorial Sloan Kettering Cancer Center, MSK, a leading cancer treatment and research center, to discover and develop novel therapeutics using generative AI for up to six programs. Under the terms of the collaboration, Absci and MSK’s world-renowned cancer research teams will co-develop therapeutics using Absci’s Integrated Drug Creation(TM) platform. “MSK has an incredible record of groundbreaking translational and clinical innovations in oncology,” said Sean McClain, Founder & CEO of Absci. “By combining MSK’s research expertise with our generative AI drug creation platform, we have the potential to unlock critical advances toward treating this devastating disease.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
- ABSI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Absci management to meet with Truist
- Absci price target lowered to $6 from $8 at KeyBanc
- Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024